Dr. Reddy’s Laboratories Ltd. announced that it has received permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act. In September 2020, Dr. Reddy’s…
Dr. Reddy’s Laboratories has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5 °C, becoming the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to further minimize environmental impact. The Company has committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 55 percent…
Dr. Reddy’s Laboratories Ltd, a Hyderabad-based integrated pharmaceutical company committed to providing affordable and innovative medicines for healthier lives, announced that it has completed the acquisition of select divisions of Wockhardt Limited’s branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives. The business comprises of a…
Dr. Reddy’s Laboratories Ltd. announced that it has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs.1850 Crores. The business comprises of a portfolio of 62 brands…
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced that based on the recommendations of the Nomination, Governance and Compensation Committee, its Board of Directors have appointed GV Prasad, presently Vice-Chairman and CEO as the “Chairman and CEO” and Satish Reddy as “Vice-Chairman” in addition to his present role of Managing Director and COO, effective from…